Minocycline compounds and methods of use thereof

1. A method of treating a human subject for complicated Skin and Skin Structure Infections, comprising orally administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein gastrointestinal (GI) adverse events (AEs) associated with treatment are mild.

2. The method of claim 1 , wherein said salt is a hydrochloride salt.

3. The method of claim 1 , wherein said salt is a tosylate salt.

4. The method of claim 1 , wherein said subject is suffering from injury, major abscess, or cellulitis.

5. The method of claim 4 , wherein said injury is a traumatic injury.

6. The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at dose of about 100 mg to about 300 mg per day.

7. The method of claim 6 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 200 mg per day.

8. The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline has a clinical success rate of treating an infection of greater than about 93.2%.

9. The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline has a microbiologically evaluable clinical success rate of treating an infection of greater than about 93.7%.

10. A pharmaceutical composition comprising from about 100 to about 300 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof and a pharmaceutically acceptable carrier for oral administration.

11. The pharmaceutical composition of claim 10 , wherein said composition comprises about 200 mg of said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline.

12. A pharmaceutical composition comprising from about 50 to about 150 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof and a pharmaceutically acceptable carrier for intravenous administration.

13. The pharmaceutical composition of claim 12 , wherein said composition comprises about 100 mg of said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline.

14. The pharmaceutical composition of claim 10 , wherein said composition comprises about 150 mg of said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline.

15. The method of claim 1 , wherein said skin and skin structure infections are caused by Staphylococcus aureus, Streptococci , or a combination thereof.

16. The method of claim 15 , wherein said Staphylococcus aureus is methicillin-resistant Staphylococcus aureus (MRSA), or methicillin-susceptible Staphylococcus aureus (MSSA).

17. The method of claim 15 , wherein said Streptococci is beta Streptococci.

18. The method of claim 15 , wherein said Streptococci is Streptococcus pyogenes.

19. The method of claim 1 , wherein said skin and skin structure infections are characterized by the presence of one or more of erythema, edema, and induration.

20. The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered once per day.

21. The method of claim 1 , wherein said subject is treated up to and including about 14 days, up to and including about 10 days, up to and including about 9 days, up to and including about 8 days, or up to and including about 7 days, such that said subject is treated.

22. The method of claim 1 , wherein GI adverse events (AEs) associated with treatment do not result in discontinuation of therapy.

23. The method of claim 6 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 300 mg per day.